5 Key Takeaways

• 1

  A study at a Vancouver obesity clinic found female sex may predict a hyper-response to GLP-1 analogues for weight loss.

• 2

  The study analyzed data from 483 adults with a BMI of at least 30 kg/m² who used semaglutide or liraglutide.

• 3

  Participants were categorized into three response groups based on total body weight loss outcomes.

• 4

  The average total body weight loss across the cohort was 12.2%, with 33.8% classified as hyper-responders.

• 5

  The study highlighted the need for future research to identify biomarkers linked to weight loss outcomes.